Inmagene Exercises Option for Two HutchMed Candidates in $460 Million Deal

Inmagene Biopharma of Shanghai has exercised options to acquire two clinical stage assets from HutchMed, also a Shanghai-based company. In 2021, Inmagene acquired options to four HutchMed assets including IMG-007 and IMG-004 in a deal worth up to $920 million, and it has been responsible for pre-clinical and clinical work on the two candidates since then. To pay for the option, Inmagene will transfer 7.5% of its shares for global rights to the two candidates for immunological indications. For each candidate, Inmagene will also be responsible for up to $95 million in development milestones and $135 million in commercial payments. More details....

Share this with colleagues: